PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,666,000 | -58.0% | 183,126 | -3.5% | 0.01% | -56.2% |
| Q4 2021 | $3,968,000 | -38.5% | 189,845 | -24.9% | 0.02% | -50.0% |
| Q3 2021 | $6,456,000 | -30.8% | 252,679 | -5.3% | 0.03% | -37.3% |
| Q2 2021 | $9,333,000 | -3.8% | 266,891 | -8.4% | 0.05% | -20.3% |
| Q1 2021 | $9,704,000 | +299.5% | 291,320 | +211.2% | 0.06% | +236.8% |
| Q4 2020 | $2,429,000 | +126.4% | 93,625 | -13.8% | 0.02% | +90.0% |
| Q3 2020 | $1,073,000 | +206.6% | 108,672 | +7.2% | 0.01% | +150.0% |
| Q2 2020 | $350,000 | +56.2% | 101,408 | +38.8% | 0.00% | +33.3% |
| Q1 2020 | $224,000 | -39.1% | 73,070 | +4.3% | 0.00% | -40.0% |
| Q4 2019 | $368,000 | +68.8% | 70,053 | +65.8% | 0.01% | +25.0% |
| Q3 2019 | $218,000 | -12.8% | 42,260 | +2.1% | 0.00% | 0.0% |
| Q2 2019 | $250,000 | +14.2% | 41,374 | +36.5% | 0.00% | -20.0% |
| Q1 2019 | $219,000 | +1.4% | 30,305 | +2.5% | 0.01% | 0.0% |
| Q4 2018 | $216,000 | – | 29,572 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |